Clinical Characteristics of the Patients at the Time of the Study
| Case . | Age/Sex . | Clinical Status . | Peripheral Blood . | Ph+/Total Metaphases* . | BCR-ABL Junction . | Time From Diagnosis (mos) . | Previous Therapy . | |
|---|---|---|---|---|---|---|---|---|
| WBC (×109/L) . | Plt (×109/L) . | |||||||
| 1 | 49/M | CP | 43 | 442 | 25/25 | b3a2 | 0 | — |
| 2 | 44/M | CP | 18 | 478 | 25/25 | b3a2 | 4 | HU |
| 3 | 58/F | CP | 12 | 349 | 20/20 | b3a2 | 12 | HU |
| 4 | 64/F | CP | 13 | 463 | 22/22 | b3a2 | 0 | — |
| 5 | 40/F | CP | 40 | 207 | 25/25 | b3a2 | 16 | HU, IFN-α |
| 6 | 59/F | CP | 67 | 519 | 15/15 | b3a2 | 0 | — |
| 7 | 40/M | CP | 162 | 264 | 20/20 | b3a2 | 0 | — |
| 8 | 49/M | CP | 69 | 305 | 30/30 | b2a2 | 0 | — |
| 9 | 54/M | CP | 87 | 555 | 20/20 | b3a2 | 0 | — |
| 10 | 64/F | CP | 54 | 456 | 30/30 | b2a2 | 0 | — |
| Case . | Age/Sex . | Clinical Status . | Peripheral Blood . | Ph+/Total Metaphases* . | BCR-ABL Junction . | Time From Diagnosis (mos) . | Previous Therapy . | |
|---|---|---|---|---|---|---|---|---|
| WBC (×109/L) . | Plt (×109/L) . | |||||||
| 1 | 49/M | CP | 43 | 442 | 25/25 | b3a2 | 0 | — |
| 2 | 44/M | CP | 18 | 478 | 25/25 | b3a2 | 4 | HU |
| 3 | 58/F | CP | 12 | 349 | 20/20 | b3a2 | 12 | HU |
| 4 | 64/F | CP | 13 | 463 | 22/22 | b3a2 | 0 | — |
| 5 | 40/F | CP | 40 | 207 | 25/25 | b3a2 | 16 | HU, IFN-α |
| 6 | 59/F | CP | 67 | 519 | 15/15 | b3a2 | 0 | — |
| 7 | 40/M | CP | 162 | 264 | 20/20 | b3a2 | 0 | — |
| 8 | 49/M | CP | 69 | 305 | 30/30 | b2a2 | 0 | — |
| 9 | 54/M | CP | 87 | 555 | 20/20 | b3a2 | 0 | — |
| 10 | 64/F | CP | 54 | 456 | 30/30 | b2a2 | 0 | — |
Abbreviations: WBC, white blood cell counts; Plt, platelet counts; CP, chronic phase; HU, hydroxyurea.
Number and type of bone marrow metaphases obtained after routine cytogenetic analysis of freshly aspirated bone marrow at the time of study.